BERKELEY, Calif. and OSS, The Netherlands, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a
biopharmaceutical company with three distinct immunotherapy technologies, announced today that Hans van Eenennaam, Ph.D., chief
operational officer and executive director of Aduro Biotech Europe, and John Dulos, Ph.D., principal scientist, will be
honored tonight by the Intellectual Property Owners Education Foundation (IPOEF) as winners of the 43rd Inventor of the Year Award
for their work relating to the discovery of KEYTRUDA® (pembrolizumab). KEYTRUDA is marketed by Merck & Co., Inc.,
Kenilworth, NJ, USA (known as MSD outside the U.S. and Canada) and is the first FDA-approved PD-1 inhibitor for the treatment of
select cancers.
“It is an honor to have been part of the team whose work led to the discovery of KEYTRUDA and positively impacted the lives of
many cancer patients,” said Dr. van Eenennaam. “Now as part of Aduro Biotech Europe, where we are focused on developing novel
B-select antibodies to modulate the immune system, we are pleased to be collaborating once again with the MSD team on what we
believe to be the best-in-class anti-CD27 therapeutic antibody.”
Dr. Dulos, principal scientist and project team lead for Aduro’s anti-APRIL BION-1301 program, commented, “As a scientist, it is
incredibly satisfying to have been part of a team whose discoveries today are having a meaningful impact on the lives of many
patients with several cancer types. We thank the Intellectual Property Owners Education Foundation for this honor and will
continue to leverage our knowledge and discoveries in the field of immuno-oncology with the aim of helping cancer patients in
need.”
Hans van Eenennaam, Ph.D., a chemist by training, has nearly 15 years of experience in the pharmaceutical and biotechnology
industry and in-depth expertise in the field of immunology. He currently serves as chief operational officer and executive
director of Aduro Biotech Europe, where he leads the development of new anti-cancer antibodies using the company’s proprietary
B-select antibody technology. Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operational
officer of BioNovion, a company he co-founded in 2011 to focus on the development of innovative therapeutic antibodies in the field
of immuno-oncology. He is named as inventor on seven pending and granted patent families, including the patents for KEYTRUDA,
and an author on over 25 publications. Dr. van Eenennaam received his doctorate in autoimmune biochemistry (cum laude) from
Radboud University Nijmegen, the Netherlands.
John Dulos, Ph.D., an immunologist with more than 20 years of experience in the pharmaceutical and biotechnology industry, is a
leader in the field of immunology, oncology and infectious diseases. He currently serves as principal scientist at Aduro Biotech
Europe where he oversees research and development of the company’s proprietary anti-APRIL (A PRoliferation-Inducing
Ligand)-targeting monoclonal antibody, BION-1301, for the treatment of multiple myeloma. Throughout his career at multiple
companies, Dr. Dulos has applied his expertise in in vitro and in vivo pharmacology of small molecules, vaccines
and antibodies from preclinical development through Phase 2 clinical studies. He is named as an inventor on two patent
applications relating to KEYTRUDA and an author on 16 peer-reviewed publications, including lead authorship on a 2012 paper that
first described the immune stimulating activity of KEYTRUDA (Journal of Immunotherapy 35:169-78). Dr. Dulos received his doctorate
from Utrecht University in the Netherlands.
About the IPOEF Inventor of the Year Award
Each year, the IPOEF recognizes outstanding recent inventions with its annual Inventor of the Year Award.
In 2016, the foundation is celebrating innovation that has led to breakthroughs in cancer treatment by honoring the inventors of
six drugs in the field of immunotherapy oncology treatment, including Merck & Co.’s KEYTRUDA®. To learn more about
the IPOEF and this award, visit www.ipoef.org.
About the Aduro - MSD Collaboration
BioNovion B.V. and MSD, through a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, entered into a worldwide license agreement
in 2014 for the development and commercialization of CD27 antibody agonists, and BioNovion received an up-front payment of $15
million. In 2015, BioNovion was acquired by Aduro Biotech and became its subsidiary, Aduro Biotech Europe B.V.
Under the agreement, a Joint Research Committee was formed to advance the program. Aduro has been reimbursed for certain
research activities and is eligible to receive future development, commercial and net sales milestone payments. In addition, Aduro
is eligible to receive royalties in the mid-single digits to low teens based on any net sales of the product, if it is approved for
marketing.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that
transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural
immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious
diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to
express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment
for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Additionally, a
personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s
tumor. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations
concerning, among other things, the potential for our technology platforms, plans, and the potential for eventual regulatory
approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,”
“will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar
expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties
that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history
of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize
our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our
ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry
and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability
to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in
greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter
ended September 30, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press
release.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 press@aduro.com
